1. Search history.
| Date | Search results |
| Initial version of the review (all years to January 2003) | From a total of 169 references identified by electronic searches and handsearching, we retrieved 20 papers and eight studies that met the inclusion criteria of the review. One study of subcutaneous anti‐IgE recruited adults with severe asthma (Holgate 2004a). Four studies examined intravenous or subcutaneous anti‐IgE in adults (Busse 2001; Milgrom 1999; Solèr 2001) and children (Milgrom 2001) with moderate to severe asthma, and three studies examined aerosolised or intravenous anti‐IgE in adults with mild asthma (Boulet 1997; Fahy 1997; Fahy 1999) |
| Update search results (January 2003 to 2004) | Publication of a critical review of the efficacy of omalizumab from published and unpublished clinical trials has prompted this update. For details of this publication, please see http://www.fda.gov. Two unpublished studies were identified from this report (ETOPA; Q2143G). One further unpublished study in people with co‐existing asthma and rhinitis is awaiting assessment (SOLAR) |
| Update search results (January 2004 to February 2006) | Electronic searches yielded a total of 48 new references from the Airways Group register. After exclusion of duplicates, a total of eight studies were retrieved for further scrutiny. Of these, five met the inclusion criteria (Prieto 2006; Djukanovic 2004; INNOVATE; van Rensen 2009; SOLAR). Details of studies that failed to meet the inclusion criteria are found in Characteristics of excluded studies |
| Update search results (June 2013) |
147 new references were identified by the Aiways Group register, producing an additional 11 studies that met the inclusion criteria: Bardelas 2012; Busse 2011; Chanez 2010; Garcia 2012; Gevaert 2012; Hanania 2011; Lanier 2009; Massanari 2010; NCT00096954; NCT01007149; Ohta 2009. Studies that did not meet the inclusion criteria are listed in Characteristics of excluded studies |